190 related articles for article (PubMed ID: 10202282)
1. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
2. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.
Murakami S; Satomi A; Ishida K; Murai H; Matsuki M; Hashimoto T
Cancer; 1994 Nov; 74(10):2745-8. PubMed ID: 7525035
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
Nakata B; Chung KH; Kato Y; Yamashita Y; Inui A; Arimoto Y; Maeda K; Onoda N; Sawada T; Sowa M
Br J Cancer; 1998 Jun; 77(11):1820-4. PubMed ID: 9667652
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer.
Murakami S; Sakata H; Tsuji Y; Okubo K; Hamada S; Hirayama R
Dig Surg; 2002; 19(1):9-13; discussion 14. PubMed ID: 11961349
[TBL] [Abstract][Full Text] [Related]
5. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Surg Today; 1998; 28(10):1115-7. PubMed ID: 9786595
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of preoperative and postoperative CK19 and CEA mRNA levels in peripheral blood of patients with gastric cardia cancer.
Qiao YF; Chen CG; Yue J; Ma MQ; Ma Z; Yu ZT
World J Gastroenterol; 2017 Feb; 23(8):1424-1433. PubMed ID: 28293089
[TBL] [Abstract][Full Text] [Related]
11. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
13. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
14. Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer.
Shibata M; Takekawa M
Oncology; 1999; 56(1):54-8. PubMed ID: 9885378
[TBL] [Abstract][Full Text] [Related]
15. A progressive postoperative increase in the serum level of soluble receptors for interleukin-2 is an indicator of a poor prognosis in patients with gastric cancer.
Maeta M; Saito H; Katano K; Kondo A; Tsujitani S; Makino M; Ikeguchi M; Kaibara N
Int J Mol Med; 1998 Jan; 1(1):113-6. PubMed ID: 9852207
[TBL] [Abstract][Full Text] [Related]
16. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
17. [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation].
Yu QS; Liu Y; Hou Y; Zhang F; Yi W; Wang X; Shuai J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Aug; 25(8):710-3. PubMed ID: 16152828
[TBL] [Abstract][Full Text] [Related]
18. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer.
Yasuda H; Toiyama Y; Ohi M; Mohri Y; Miki C; Kusunoki M
J Surg Oncol; 2011 Jun; 103(7):695-9. PubMed ID: 21308684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
